In a market where it is difficult to find opportunities that really deserve attention, Diego García del Río provides this analysis highlighting three companies: Achieve Life Sciences ($ACHV), Zevra Therapeutics ($ZVRA) y Crinetics Pharmaceuticals ($CRNX).
ACHV advances cytisinicline for smoking cessation; ZVRA advances MIPLYFFA in rare diseases; and CRNX approaches the PDUFA for paltusotine for acromegaly, scheduled for September 25. Each case is analyzed from key metrics, target price estimates, and market patterns, with a focus on speculative biotechs with high growth potential.
Before going into detail, you can see their vision on the valuation of these companies and a more in-depth analysis on the website of Diego Garcia del Rio.
$ACHV — Cytisinicline and the box thesis
In your opinion, Achieve Life Sciences ($ACHV) is a pre-commercial biotechnology company focused on cytisinicline, a late-stage drug for smoking cessation. The company has solid liquidity following its recent capital increase, allowing it to fund operations through 2027 without immediate dilution.
The potential market for this treatment is vast: about 1.200 billion smokers worldwide and an estimated therapy segment of $ 5.200 billion in 2028This makes cytisinicline a candidate with truly disruptive potential if it achieves regulatory approval.
The analyst consensus is optimistic, with “Buy” recommendations and target prices between 11 and $ 20, currently trading at 3,02, which represents an upside of more than 400% compared to the current level.
On the technical level, the action draws a rising wedge In intermediate markets, the first target is around $3.80, subject to a rebound in volume.
$ZVRA — Momentum in Rare Diseases
Zevra Therapeutics ($ZVRA) represents a different profile: a mid-cap with growing income thanks to MIPLYFFA, approved for idiopathic hypersomnia and in development for narcolepsy.
The company managed to reinforce its cash flow after selling a Priority Review Voucher for $150M, securing a runway through 2028. Its revenue grew by 486% year-over-year in Q2 2025, and projected sales of MIPLYFFA reach 80M USD in 2025.
The rare disease market, where ZVRA operates, is projected to USD 495.000 billion in 2033 with a CAGR of 13,8%. This makes the company a transitional case: from “medical history” to “revenue history.”
Technically, the stock has rebounded from lows of $7.16 in early September, although it remains under downward pressure. The key range is $8.50–$8.75 as immediate resistance.
$CRNX — Regulatory Window
Crinetics Pharmaceuticals ($CRNX) is positioned at a more advanced stage. Its drug paltusotine has a PDUFA decision on September 25 for acromegaly, a market estimated at more than $2.000M.
Over 1.2B USD in cash and minimal debt, CRNX has a runway until 2029, giving it an advantage over its peers. Analysts value the stock with average price targets of 74 USD, implying a revaluation potential of more than 100%.
The technical chart confirms momentum: the 50 EMA has broken above the 200 EMA (bullish crossover), and immediate resistance lies at $38. A breakout with volume could propel the price towards $45.
The analysis continues on Diego García del Río's website.
Their approach to the market focuses on combining the study of options and derivatives With a rigorous analysis of institutional flows, macroeconomic catalysts, and opportunities in high-potential sectors such as biotechnology. Throughout his career, he has developed his own methodology for interpreting volatility, gamma exposure, and dealer positioning, allowing him to anticipate risk scenarios and design strategies with favorable risk/reward ratios.
In this article we only show a part of that process; the full analysis—including a detailed reading of the option chain and tactical scenarios—is available on the website of Diego García del Río, where it publishes expanded and updated reports for readers looking to go beyond the surface of the market.